Julio Chavez

45PUBLICATIONS
255CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Biologically active moleculesEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (45)

|Aug 03, 2026
A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T-Cell Lymphoma.

|Jul 17, 2026
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

|Jul 08, 2026
Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

|Jun 12, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

|Jun 03, 2026
Managing cytokine release syndrome in hematological malignancies being treated with CAR-T cell therapy.

|May 19, 2026
From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in lymphoma therapy.

Pageof 8

Frequent Collaborators

8 joint publications

Michael Jain

5 joint publications

Jorge J Castillo

5 joint publications

Frederick Locke

4 joint publications

Olalekan Oluwole